- Case report
- Open Access
- Open Peer Review
Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
Journal of Medical Case Reportsvolume 11, Article number: 183 (2017)
Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this treatment and concomitant use of corticosteroids.
A 64-year-old caucasian man with a pulmonary adenocarcinoma associated with brain metastases received four courses of nivolumab in concomitance with a high dose of corticosteroids for his neurologic symptoms. He experienced a partial response in his brain and chest with an improvement in his general condition.
Nivolumab was effective in shrinking symptomatic brain metastases, and metastases at other sites, in a patient with non-small cell lung cancer and first-line chemotherapy failure. The effect of nivolumab was obtained despite concomitant high-dose corticosteroid therapy. Combined nivolumab and high-dose corticosteroid therapy did not induce unexpected adverse events.
Nivolumab and concomitant high-dose corticosteroid therapy was found to be efficient and well tolerated.
The standard of care for non-small cell lung cancer (NSCLC) has changed with the introduction of immune checkpoint modulators such as nivolumab, a monoclonal antibody which binds to the programmed death-1 (PD-1) receptor expressed on T cells. In phase III trials, nivolumab improved both overall survival (OS) and progression-free survival (PFS) , or only PFS  compared with docetaxel, in locally advanced or metastatic NSCLC with progression after first-line chemotherapy. In these trials, patients with unstable or untreated brain metastases were excluded and the highest permitted corticosteroid dosage was 10 mg daily prednisone (or equivalent) within the last 2 weeks.
We describe a patient with metastatic pulmonary adenocarcinoma who received nivolumab with oral corticosteroid therapy for symptomatic brain metastasis.
In June 2014, a 64-year-old caucasian man with a 40 pack-year tobacco smoking history was diagnosed with stage IV, KRAS mutated (glycine substitution at the codon 12 in exon 2), adenocarcinoma of the lung. He had detectable lung and mediastinal lymph node metastases but no brain metastasis. Between August 2014 and December 2015, he successively received cisplatin and pemetrexed, docetaxel, erlotinib, then gemcitabine. In December 2015, thoracic and mediastinal progression, as well as new vertebral, pleural, and adrenal metastases were diagnosed. He had no neurological symptoms and, consequently, brain imaging was not performed. In January 2016, he started nivolumab 3 mg/kg every 15 days.
Three days after the first infusion, left hemiparesis developed. A brain computed tomography (CT) scan showed at least four brain metastases including a right frontal lesion with significant perilesional edema consistent with the neurological symptoms (Fig. 1). He received 80 mg of oral prednisolone per day. The hemiparesis resolved within 10 days. Nivolumab dosage and time of administration were left unchanged. After 1 month, the corticosteroid dose was lowered. Imaging studies performed after four courses of nivolumab showed almost complete disappearance of the pleural and adrenal metastases, together with substantial shrinkage of the other lesions: for example, from 21 to 9 mm for the right frontal brain metastasis (Fig. 1) or from 80 to 60 and from 23 to 16 mm for the primary lung tumor in the middle lobe and the metastasis in the lower lobe of his right lung, respectively (Fig. 2). The treatment was well tolerated, although hyperthyroidism developed.
Four months after nivolumab start, the drug remained radiologically and clinically effective: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0.
The timeline summarizes clinical history and therapeutic interventions (Fig. 3).
Nivolumab is approved in Europe and United States of America (USA) for the second-line treatment of NSCLC [3, 4]. Corticosteroids have immunosuppressive effects and were therefore excluded during the pivotal trials of nivolumab. However, during nivolumab therapy, symptoms requiring corticosteroid therapy may appear. In theory, concomitant corticosteroid therapy might decrease the effectiveness of nivolumab.
In a pooled analysis of data from the KEYNOTE-001 trial, in which 550 patients with advanced NSCLC took pembrolizumab, another monoclonal antibody targeting PD-1, some patients received corticosteroid therapy to treat immune-related adverse events . PFS was not significantly different between these patients and those who did not take corticosteroids. However, pembrolizumab was discontinued during corticosteroid therapy. CheckMate 017 and Checkmate 043 evaluated the efficiency and safety of nivolumab in advanced squamous NSCLC. The pooled analysis of the data from these two trials included 248 patients given nivolumab. Immune-related adverse events requiring corticosteroid therapy were uncommon and usually low-grade events that resolved within 6 weeks in most cases. In both trials, nivolumab was also discontinued during corticosteroid therapy .
Few data are available about immunotherapy efficiency on primary or metastatic brain tumors [7, 8]. Ipilimumab has been found effective in melanoma with asymptomatic brain metastases . Of 12 patients with brain metastases from NSCLC treated with nivolumab, 7 (58%) required discontinuation of the drug because of exacerbation of their neurological symptoms . Data from available trials suggest that immunotherapy may have similar effects on brain and extracerebral metastases . NSCLC often causes brain metastases, for which no specific treatment is available. Nivolumab Italian Expanded Access Program (EAP) is a program developed in order to include patients with asymptomatic brain metastases from squamous NSCLC in clinical trials involving nivolumab . This approach aims to evaluate the efficiency and safety of nivolumab use in this subpopulation given the scarce available data. Among 372 patients, 38 patients with asymptomatic brain metastases received nivolumab. Only one patient discontinued nivolumab because of an adverse event. There was 1 complete response, 6 partial responses, and 11 stable diseases. Median PFS was 5.5 months and OS was 6.5 months. Since many patients are diagnosed stage IV NSCLC with brain metastases, the evaluation of these outcomes is of major clinical significance. These data toward nivolumab activity in brain metastases of squamous NSCLC, although preliminary, are encouraging the evaluation of nivolumab efficiency and safety in this cohort of real-life patients, who are excluded from clinical trials. This is why further investigations of immunotherapy in this subpopulation must be pursued [13, 14].
In our patient, despite the symptomatic brain metastasis and high-dose of oral corticosteroid therapy, nivolumab was highly effective on tumors at all sites and induced no unexpected severe toxicity. Thus, the high dose of corticosteroid therapy did not seem to decrease the effectiveness of nivolumab.
This original case report suggests that nivolumab may be effective and safe in patients with brain metastases from NSCLC who are taking concomitant high-dose corticosteroid therapy.
Non-small cell lung cancer
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–35.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Cancer Netw JNCCN. 2016;14(3):255–64.
Sundar R, Cho B-C, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96.
Leighl N, Gandhi L, Hellmann MD, Horn L, Ahn MJ, Garon EB, et al. Pembrolizumab for NSCLC Immune-Mediated Adverse Events and Corticosteroid Use. Oral sessions. J Thorac Oncol. 2015;10(9):S173–260.
Gettinger SN, Horn L, Ramalingam SS, Spigel DR, Paz-Ares L, Paik P, et al. 3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51:S631.
Rothermundt C, Hader C, Gillessen S. Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol. 2016;27(3):544–5.
Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P. Ipilimumab and Bevacizumab in Glioblastoma. Clin Oncol (R Coll Radiol). 2016;28(10):622–6.
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65.
Kanai O, Fujita K, Okamura M, Nakatani K, Mio T. Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. Ann Oncol. 2016;27(7):1354–6.
Cohen JV, Kluger HM. Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol. 2016;6:49.
Cortinovis D, Delmonte A, Chiari R, Catino A, Grossi F, Noberasco C, et al. P3.02c-094 Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases. J Thorac Oncol. 2017;12(1):S1336.
Lukas RV, Kumthekar P, Rizvi S, Salgia R. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol Lond Engl. 2016;12(8):1045–58.
Bui N, Woodward B, Johnson A, Husain H. Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. Curr Treat Options Oncol [Internet]. 2016;17(5). doi:10.1007/s11864-016-0400-x
No financial support was obtained.
We thank A. Wolfe, MD, for English language editing.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
All authors contributed to the writing. They have seen and approved the final version of the submitted manuscript.
Dr Toffart received personal fees from BMS and Chugai; personal fees and non-financial support from Boehringer Ingelheim, Pfizer, and Lilly; and non-financial support from Roche; during the conduct of the study.
Pr Moro-Sibilot received personal fees from BMS, Roche, MSD, Astra Zeneca, and Pfizer, during the conduct of the study.
Dr Pluchart, Dr Pinsolle, Dr Cohen, Dr Ferretti, Dr Giaj Levra, and Dr Bedouch have nothing to disclose.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
- Case report
- Pulmonary adenocarcinoma
- Brain metastasis-related symptoms
- Immunomodulating drugs